Fundamental Problems Lie Ahead in the Drug Discovery and Commercialization Process

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Journal of Investigative Medicine

• Publication date

  2006-09-01

• Fields of study

  Medicine, Chemistry, Computer Science

• Identifiers
  DOI 10.2310/6650.2006.05030PMID 17191351
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The Truth about Drug Companies: How They Deceive Us and What to Do about It

  2006cited by this paper
• On the take : how America's complicity with big business can endanger your health

  2005cited by this paper
• Launching a New Fellowship for Medical Students: The First Years of the Doris Duke Clinical Research Fellowship Program

  2005cited by this paper
• Tetrathiomolybdate protects against cardiac damage by doxorubicin in mice.

  2005cited by this paper
• Inhibition of key cytokines by tetrathiomolybdate in the bleomycin model of pulmonary fibrosis.

  2004cited by this paper
• Tetrathiomolybdate Therapy Protects Against Concanavalin a and Carbon Tetrachloride Hepatic Damage in Mice

  2004cited by this paper
• Tetrathiomolybdate Protects Against Liver Injury from Acetaminophen in Mice

  2004cited by this paper
• Surviving the Blockbuster Syndrome

  2004cited by this paper
• Fewer Drugs and Biologics Advancing from Phase I Trials to Marketplace

  2004cited by this paper
• Clinical trials. In critical condition.

  2003cited by this paper
• Tetrathiomolybdate therapy protects against bleomycin-induced pulmonary fibrosis in mice.

  2003cited by this paper
• Translating biomedical research to the bedside: a national crisis and a call to action.

  2003cited by this paper
• Millennium Downsized

  2003cited by this paper
• Central challenges facing the national clinical research enterprise.

  2003cited by this paper
• U.K. Probes Public Opposition to GM Crops

  2003cited by this paper
• In Critical Condition

  2003cited by this paper
• Science as a Way of Life: Perplexities of a Physician-Scientist

  2003cited by this paper
• Treatment of Wilson disease with ammonium tetrathiomolybdate: III. Initial therapy in a total of 55 neurologically affected patients and follow-up with zinc therapy.

  2003cited by this paper
• Ruth L. Kirschstein, MD

  2001cited by this paper
• Crises in Academic Medicine

  2001cited by this paper
• Financial Incentive for Young Clinical Researchers

  2001cited by this paper
• Innovation in the pharmaceutical industry

  2000cited by this paper
• The Physician‐Scientist: Career Issues and Challenges at the Year 2000

  2000cited by this paper
• When Pharma Merges, R&D Is the Dowry

  2000cited by this paper
• Novel pharmacologic therapies for cystic fibrosis.

  1999cited by this paper
• How many leads from HTS?

  1999cited by this paper
• "Innovation in the Pharmaceutical Industry".

  1978cited by this paper
• Presidential address.

  1970cited by this paper

• Drug Repurposing for Rare Diseases.

  2021cites this paper
• Current and Future Strategies for Improving Drug Discovery Efficiency

  2015cites this paper
• Academic drug discovery centres: the economic and organisational sustainability of an emerging model.

  2014cites this paper
• Policies to increase the social value of science and the scientist satisfaction. An exploratory survey among Harvard bioscientists.

  2014cites this paper
• Bridging the medical knowledge and practice gap: antecedents of successful scientist-physician collaboration

  2014cites this paper
• Insurance companies' perspectives on the orphan drug pipeline.

  2013cites this paper
• Is cost-effective healthcare compatible with publicly financed academic medical centres?

  2013cites this paper
• THERAPEUTIC STRATEGIES DRUG DISCOVERY TODAY Drug Discovery Today : Therapeutic Strategies

  2012cites this paper
• Orphan/rare drug discovery through drug repositioning

  2011cites this paper
• Orphan drug: Development trends and strategies

  2010cites this paper
• Drug discovery dilemma and Cura quartet collaboration.

  2009cites this paper
• Drug development for orphan diseases in the context of personalized medicine.

  2009cites this paper
• Drug discovery: new models for industry-academic partnerships.

  2009cites this paper
• The case for open‐access chemical biology

  2009cites this paper